Antidepressants in Anxiety: A Comprehensive Approach to Efficacy and Mechanisms of Action.
PDF (Português (Brasil))

Keywords

Antidepressants
anxiety

How to Cite

Vasconcelos, J. L. M., Manfroi , A., Filho , A. C. G., Pinaty , C. M. Z., Evangelista , D. F., Gregory , G. G., Fritsch , G. G., Brunetta, I. de C., Barros , I. F., Gonçalves , K. M., Brunetta , L. de C., Rosa , L. G. S., Lacerda, M. V. M. de B., Figueiredo, M. C. de A., Menezes , M. E. C. de, Cenci , M. E. F., Sansão, M. E. M., Filho , M. G., Ceron , N. S. M., Dantas , T. T. G., & Oliveira, T. R. de. (2024). Antidepressants in Anxiety: A Comprehensive Approach to Efficacy and Mechanisms of Action. Brazilian Journal of Implantology and Health Sciences, 6(1), 1716–1722. https://doi.org/10.36557/2674-8169.2024v6n1p1716-1722

Abstract

This paper conducts a comprehensive literature review on the role of antidepressants in the treatment of anxiety. The analysis includes controlled clinical trials and systematic reviews addressing the efficacy of different classes of antidepressants, with a primary focus on Selective Serotonin Reuptake Inhibitors (SSRIs) and tricyclic antidepressants. The results indicate that SSRIs, such as escitalopram, consistently demonstrate efficacy in reducing anxiety symptoms compared to placebos. Additionally, tricyclic antidepressants, although less commonly prescribed, have proven effective in specific situations, such as in the treatment of social anxiety disorder. The research emphasizes the importance of personalized treatment, considering factors such as the side effect profile, comorbidities, and individual patient characteristics. This personalized approach emerges as crucial for optimizing clinical outcomes and minimizing potential adverse effects.

https://doi.org/10.36557/2674-8169.2024v6n1p1716-1722
PDF (Português (Brasil))

References

Baldwin, D. S., Ajel, K., Masdrakis, V. G., Nowak, M., Rafiq, R., & Raphael, J. (2017). Efficacy of Escitalopram in the Treatment of Social Anxiety Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Clinical Psychopharmacology, 37(5), 550-558.

Bandelow, B., Sher, L., Bunevicius, R., Hollander, E., Kasper, S., Zohar, J., ... & Möller, H. J. (2018). Guidelines for the Pharmacological Treatment of Anxiety Disorders, Obsessive-Compulsive Disorder and Posttraumatic Stress Disorder in Primary Care. International Journal of Psychiatry in Clinical Practice, 22(2), 88-100.

Reynolds, C. F., Anderson, G. M., Brummett, B. H., & Smith, A. R. (2019). Imipramine for Social Anxiety Disorder: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial. Journal of Clinical Psychopharmacology, 39(1), 29-36.

Anderson, R. H., Williams, S. E., Johnson, M. R., & Brown, C. D. (2020). Tailoring Antidepressant Therapy for Anxiety: A Comprehensive Approach. Journal of Anxiety Disorders, 68, 102196.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2024 José Lucas Moura Vasconcelos, Amabile Manfroi , Antônio Carlos Gargioni Filho , Carla Maria Zanelli Pinaty , Danyllo Fagundes Evangelista , Gilmara Gabrielli Gregory , Giordana Gregório Fritsch , Iara de Campos Brunetta, Izadora Fernanda Barros , Kauara Marcelino Gonçalves , Lara de Campos Brunetta , Leonardo Gomes Silva Rosa , Marcos Vinicius Maldonado de Barros Lacerda, Maria Clara de Alencar Figueiredo, Maria Eduarda Coelho de Menezes , Maria Eduarda Fornari Cenci , Maria Eduarda Miranda Sansão, Miguel Gramulha Filho , Nathalia Sofia Mayer Ceron , Thais Torres Galindo Dantas , Thiago Rodrigues de Oliveira